imatinib mesylate has been researched along with Familial Primary Pulmonary Hypertension in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, LL; Clemons, B; Douthitt, A; Galkin, A; Gandjeva, A; Garcia, E; Guimond, D; Kennedy, M; Osterhout, R; Salter-Cid, L; Sitapara, R; Slee, D; Tuder, RM; Zisman, LS | 1 |
| Akaki, K; Asano, R; Hia, F; Inagaki, T; Ishibashi, T; Ishibashi-Ueda, H; Manabe, Y; Masaki, T; Mino, T; Mori, H; Morinobu, A; Morita, S; Nakaoka, Y; Nakatsuka, Y; Ogo, T; Okazawa, M; Sato, A; Takeuchi, O; Tsujimura, T; Uehata, T; Vandenbon, A; Yaku, A; Yoshinaga, M | 1 |
| Barst, RJ; Bourge, RC; Feldman, J; Frost, AE; Galié, N; Ghofrani, HA; Gómez-Sánchez, MA; Grimminger, F; Grünig, E; Hassoun, PM; Hoeper, MM; Lawrence, D; Morrell, NW; Peacock, AJ; Quinn, DA; Satoh, T; Simonneau, G; Tapson, VF; Torres, F | 1 |
| Humbert, M | 1 |
| Mucke, H | 1 |
| Aboagye, EO; Ashek, A; Barnes, G; Cotroneo, E; Cupitt, J; Dabral, S; Dubois, O; El-Bahrawy, MA; Fang, W; Gibbs, JS; Gsell, W; He, JG; Howard, LS; Jones, H; Nguyen, QD; Pullamsetti, SS; Tomasi, G; Wang, L; Wilkins, MR; Zhao, L | 1 |
| Arita, N; Arita, S; Hikasa, Y | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Domenighetti, G; Huber, LC; Speich, R; Treder, U; Ulrich, S | 1 |
| Abe, K; Alvarez, D; Alzoubi, A; Järvinen, TA; Komatsu, M; Mann, D; McMurtry, IF; O'Neill, K; Oka, M; Ruoslahti, E; Toba, M; Urakami, T | 1 |
| Akagi, S; Fuke, S; Ito, H; Kohno, K; Kusano, KF; Matsubara, H; Miura, A; Miura, D; Morita, H; Nagase, S; Nakamura, K; Nishii, N; Ogawa, A; Ohe, T; Oto, T; Otsuka, F; Yamanaka, R; Yutani, C | 1 |
| Dahal, BK; Ghofrani, HA; Kojonazarov, B; Kwapiszewska, G; Markart, P; Marsh, LM; Meinhardt, A; Olschewski, A; Preissner, KT; Schermuly, RT; Seeger, W; Steinhoff, M; Taube, C; Weissmann, N; Wygrecka, M | 1 |
| Chaumais, MC; De Man, FS; Dorfmüller, P; Eddahibi, S; Fadel, E; François, C; Girerd, B; Guignabert, C; Huertas, A; Humbert, M; Lecerf, F; Montani, D; Perros, F; Tu, L | 1 |
| Bossone, E; D'Amore, C; Dellegrottaglie, S; Gargiulo, P; Leosco, D; Losco, T; Marciano, C; Musella, F; Perrone-Filardi, P; Rengo, G; Savarese, G | 1 |
3 review(s) available for imatinib mesylate and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
The role of imatinib in the treatment of pulmonary hypertension.
Topics: Animals; Benzamides; Clinical Trials as Topic; Disease Progression; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2013 |
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension.
Topics: Benzamides; Endothelin Receptor Antagonists; Epoprostenol; Exercise; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Phosphodiesterase 5 Inhibitors; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome; Walking | 2013 |
2 trial(s) available for imatinib mesylate and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Topics: Adolescent; Adult; Aged; Benzamides; Double-Blind Method; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hematoma, Subdural; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2013 |
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Topics: Adult; Aged; Animals; Benzamides; Cell Division; Dichloroacetic Acid; Disease Models, Animal; Drug Monitoring; Familial Primary Pulmonary Hypertension; Female; Fibroblasts; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Glycolysis; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Indoles; Lung; Male; Middle Aged; Monocrotaline; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sunitinib; Young Adult | 2013 |
9 other study(ies) available for imatinib mesylate and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
Topics: Animals; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; MicroRNAs; Monocrotaline; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats | 2022 |
Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
Topics: Animals; Biomarkers; Cytokines; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Imatinib Mesylate; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Leukocytes, Mononuclear; Macrophages, Alveolar; Mice; Platelet-Derived Growth Factor; Pulmonary Arterial Hypertension; Pulmonary Artery; Ribonucleases; RNA Stability; Vascular Remodeling | 2022 |
Impression, sunset.
Topics: Benzamides; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Piperazines; Pyrimidines | 2013 |
Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.
Topics: Animals; Benzamides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Hypertension, Pulmonary; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension.
Topics: Adult; Benzamides; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Humans; Imatinib Mesylate; Injections, Intravenous; Piperazines; Prostaglandins; Protein Kinase Inhibitors; Pyrimidines | 2014 |
A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Topics: Administration, Sublingual; Amino Acid Sequence; Animals; Arterial Occlusive Diseases; Benzamides; Drug Delivery Systems; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Imatinib Mesylate; Infusions, Intravenous; Injections, Intravenous; Male; Molecular Sequence Data; Peptides; Piperazines; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vasodilator Agents | 2014 |
Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
Topics: Adolescent; Adult; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Child; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myocytes, Smooth Muscle; Piperazines; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
PAR-2 inhibition reverses experimental pulmonary hypertension.
Topics: Adolescent; Adult; Animals; Antibodies, Neutralizing; Becaplermin; Benzamides; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oligopeptides; Piperazines; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, PAR-2; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Signal Transduction; Time Factors; Transfection; Tryptases; Young Adult | 2012 |
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Topics: Animals; Benzamides; Benzimidazoles; Case-Control Studies; Crk-Associated Substrate Protein; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Mice; Monocrotaline; Myocytes, Smooth Muscle; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Quinazolines; Quinolones; Rats; Signal Transduction | 2012 |